PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1895
https://www.valueinhealthjournal.com/article/S1098-3015(18)35197-0/fulltext
Title : PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35197-0&doi=10.1016/j.jval.2018.09.1895
First page :
Section Title :
Open access? : No
Section Order : 1253
Categories :
Tags :
Regions :
ViH Article Tags :